Can I take Wegovy if I have gallstones?

Does Wegovy raise the risk of gallbladder problems?

This is one of the more common questions our prescribers receive, and it deserves a straight answer. Wegovy's active ingredient, semaglutide, has been associated with gallbladder-related side effects in clinical trials and in post-marketing reports. The most frequently reported are gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). In the large STEP 1 trial, published in the New England Journal of Medicine, gallbladder disorders appeared more often in the semaglutide group than in the placebo group.

Part of this is the medicine's mechanism. Semaglutide slows gastric emptying and significantly reduces appetite, which leads to reduced calorie intake and weight loss. Rapid or substantial weight loss (by any route, including surgery and dieting) shifts the balance of cholesterol and bile salts in bile, making it more likely to crystallise into stones. GLP-1 medicines may also reduce gallbladder motility, meaning bile sits longer and concentrates. Neither of these effects is unique to Wegovy, but they are real, and they matter when a person already has gallstone disease.

The NHS medicines page for semaglutide lists gallbladder problems among the side effects to be aware of, alongside guidance on when to seek help. If you experience sudden, severe pain in your upper right abdomen (particularly after eating, and especially if accompanied by fever or jaundice) contact a clinician the same day.

If I already have gallstones, does that rule Wegovy out?

Not automatically. Having a history of gallstones is different from having an acutely inflamed or obstructed gallbladder right now. For someone with asymptomatic gallstones discovered incidentally, a prescriber might judge that the cardiometabolic benefits of treating obesity outweigh the risk of destabilising the gallstones — particularly if the stones have been stable for years. For someone with recurrent biliary colic or a recent episode of cholecystitis, the calculation looks different. If you want a fuller picture of how this condition affects eligibility, our page on whether you can take Wegovy with gallstones walks through the key considerations.

A common misconception worth setting aside gently: people sometimes assume that because GLP-1 medicines cause weight loss gradually, the gallbladder risk doesn't apply to them. In fact, the same biological mechanism that makes rapid crash-dieting problematic for the gallbladder applies here too, steady, sustained weight loss still shifts bile composition, and the gallbladder motility effect is present from the outset.

If you have had your gallbladder removed (cholecystectomy), the picture changes again. Without a gallbladder, the specific risks of stone formation and cholecystitis no longer apply in the same way, though your prescriber will still consider your broader digestive history. You can read more about the eligibility factors our prescribers consider on our overview of who can take Wegovy.

The BMI thresholds are a starting point, not the finish line. You can check the licensed BMI criteria on our guide to BMI requirements for Wegovy, but your gallbladder history will be part of a broader conversation.

What should I tell my prescriber, and what happens during assessment?

Transparency is the most useful thing you can bring to a consultation. If you have a gallstone history, share the details: when the stones were diagnosed, whether you have had symptoms, whether you have been treated or had surgery, and whether you are currently symptomatic. The same applies if you are taking ursodeoxycholic acid or any other medication for gallbladder disease.

At nume, every consultation is read personally by a GPhC-registered Independent Prescriber, a real clinician, not an automated system. They will review your health history in full before making any prescribing decision, and they may ask follow-up questions or recommend speaking to your GP first. Our clinical team takes situations like this seriously, and no treatment is approved simply because someone meets the BMI threshold on paper.

If treatment is approved, it is worth knowing that monitoring matters throughout. The NHS England guidance on weight management injections makes clear that ongoing clinical review (not just an initial sign-off) is the standard for these medicines. At every repeat, a prescriber reviews your case again before anything is dispensed. Intercurrent illness is one area that comes up regularly, and if you are wondering whether you should take Wegovy if you have the flu, or more broadly what to do when you have the flu and are on Wegovy, we cover both of those scenarios in dedicated guidance. You can find answers to other common clinical questions in our FAQs, or explore the broader range of treatments on our weight-loss overview.

If you have questions about how cost fits into the decision, our Wegovy cost and access page sets out what is included in a private prescription. When you feel ready, you can start your free consultation and have your case reviewed the same day.